Drug Profile


Alternative Names: Captisol-enabled IV-Ziprasidone; CP 88059; CP 88059 01; CP-88059-1; Geodon; ME 2112; RQ-00000003; Zeldox; Ziprasidone hydrochloride; Ziprasidone mesylate

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Meiji Seika Pharma; Pfizer; RaQualia Pharma
  • Class Antipsychotics; Piperazines; Thiazoles
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bipolar disorders; Schizophrenia
  • No development reported Anxiety disorders
  • Discontinued Bipolar depression

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 03 Aug 2017 Chemical structure information added
  • 21 Jun 2017 Ziprasidone is still in phase III trials for Bipolar disorders (In adolescents, In children) in USA (PO, Capsule) (NCT02075047)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top